ISAR Research Updates
Research topics prioritised by the ISAR Steering Committee for 2021:
Phenotypic Characteristics, Comorbidities and Response to Therapeutic Interventions Associated with Non-Type 2 Asthma (EMBER)
Effectiveness of Biologics (by classes) in Patients with Different Combination of T2 Biomarkers (IGNITE)
Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Therapies: a Post Authorization Safety Study (PASS).
Biologic Patterns, Clinical Outcomes and Health Resource Utilization (CLEAR)
Impact of Initiating Biologics In Patients on Long Term OCS or Frequent Rescue Steroids (GLITTER)
Research topics prioritised by the ISAR Steering Committee for 2020:
Define Responders and Non-Responders to Biologics and Describe Their Characteristics Overall and Per Biologic (BEAM)
Describe the Clinical Outcome Before and After Biologic Treatment by Biologic Class, by Individual Biologic, and by Subgroups of Baseline Characteristics (LUMINANT)
Previously, ISAR Steering Committee (ISC) members voted for 1 fully funded project and 4 academic projects. Henceforth from 2019, the ISC members will vote for 2 fully funded projects.
Research topics prioritised by the ISC members for the year 2019:
Impact of Co-Morbidity in Severe Asthma (PRISM)
Comparative effectiveness across severe asthma biologic classes (Anti-IL5 vs Anti lgE) in patients eligible for both modalities (FIRE)
The following research topics were prioritized during the ISC Closed session for 2019 and are open to researchers to join and lead. Submit your interest through our website or contact your country lead for further details.
|What is the OCS landscape: annual consumption, prevalence, outcomes and side-effects of long-term OCS users?||Read More|
|Describe the characteristics of severe asthma patients with inflammatory phenotypes and FEV1 <40%?||Read More|
|What is the characterization of health disparities across countries?||Read More|
|What are the criteria for choosing and switching between similar biological treatment options in patients with atopic and non-atopic severe eosinophilic asthma?||Read More|
Research topic prioritized by the ISAR steering committee for the second year 2018:
The Characterization and Comparison of Eosinophilic and Non-Eosinophilic Phenotypes of Severe Asthma
Group characterization and feasibility numbers were presented at the REG summit 2019 during the ISAR Research Collaborator Meeting.
Hidden Severe Asthma in UK Primary Care*
Biologics in Severe Asthma: Utilization Patterns, Causes for Discontinuation and Switching and Adverse Outcomes* (SUNNIE)
Biomarker Relatability in the International Severe Asthma Registry (BRISAR)
The Role of Exacerbations on Lung Function Trajectory*
Identify Predictors (e.g. biomarkers) of Response to Biologics
Hidden Chronic Asthma within the COPD/ACO Population
Onset of Asthma in Severe Asthma Patients (PATH)
Relationship between Socioeconomic Status and Asthma Outcome (RADIANT)
Research topic prioritized by the ISAR steering committee for the inaugural year 2017:
Demographic and Clinical Characteristics of Severe Asthma Patients Worldwide
4,990 patients from five countries have contributed to this first research project of ISAR.